JFG
LCTX icon

Jefferies Financial Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Jefferies Financial Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,192
Closed -$69.8K – 1869
2026
Q1 		$69.8K Sell
44,192
-14,898
-25% -$25.1K ﹤0.01% 1628
2025
Q4 		$98.7K Sell
59,090
-3,110
-5% -$5.38K ﹤0.01% 1704
2025
Q3 		$105K Buy
+62,200
New +$73.6K ﹤0.01% 1336
2023
Q2 		– Sell
-23,998
Closed -$36K – 1870
2023
Q1 		$36K Buy
+23,998
New +$33.5K ﹤0.01% 1512

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jefferies Financial Group's LCTX Position: Q2 2026 in Review

Jefferies Financial Group sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 44,192 shares — an estimated $69.8K sold.

Jefferies Financial Group first reported a position in LCTX in Q1 2023 and held it in 4 quarters. The position peaked at $105K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Jefferies Financial Group reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 44,192 Lineage Cell Therapeutics shares in Q2 2026, an estimated $69.8K.
  • Jefferies Financial Group first reported a position in Lineage Cell Therapeutics in Q1 2023 and held it in 4 quarters.
  • Jefferies Financial Group's Lineage Cell Therapeutics position peaked at $105K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.